Shares of Chimerix Inc. (NASDAQ:CMRX) traded up 3% during mid-day trading on Wednesday . The company traded as high as $4.22 and last traded at $4.14, with a volume of 194,169 shares trading hands. The stock had previously closed at $4.02.

A number of analysts have recently weighed in on CMRX shares. Zacks Investment Research upgraded shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Wednesday, May 11th. FBR & Co restated a “hold” rating on shares of Chimerix in a research note on Sunday, July 17th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Chimerix has a consensus rating of “Hold” and a consensus price target of $16.98.

The firm’s market cap is $193.17 million. The stock’s 50 day moving average is $3.98 and its 200 day moving average is $5.39.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.09. The business had revenue of $1.20 million for the quarter, compared to the consensus estimate of $2.79 million. On average, equities research analysts forecast that Chimerix Inc. will post ($2.06) earnings per share for the current fiscal year.

In other news, Director Ernest Mario bought 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 11th. The stock was acquired at an average cost of $4.85 per share, with a total value of $121,250.00. Following the completion of the purchase, the director now owns 297,240 shares of the company’s stock, valued at $1,441,614. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO M Michelle Berrey bought 13,188 shares of the firm’s stock in a transaction that occurred on Friday, June 24th. The stock was purchased at an average cost of $3.69 per share, with a total value of $48,663.72. Following the completion of the purchase, the chief executive officer now directly owns 258,821 shares of the company’s stock, valued at approximately $955,049.49. The disclosure for this purchase can be found here.

Several institutional investors have recently added to or reduced their stakes in the stock. Morgan Stanley boosted its position in Chimerix by 96.7% in the fourth quarter. Morgan Stanley now owns 187,163 shares of the biopharmaceutical company’s stock valued at $1,674,000 after buying an additional 92,005 shares in the last quarter. Trexquant Investment LP boosted its position in Chimerix by 453.5% in the fourth quarter. Trexquant Investment LP now owns 131,184 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 107,484 shares in the last quarter. Finally, Jennison Associates LLC boosted its position in Chimerix by 67.9% in the fourth quarter. Jennison Associates LLC now owns 1,273,779 shares of the biopharmaceutical company’s stock valued at $11,400,000 after buying an additional 515,029 shares in the last quarter.

Chimerix, Inc a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.